GW Pharma's cannabis medicine to win UK approval

My Account
Logout

Create an Evening Standard Account

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Welcome! Sign in here

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Forgot your password ?

Registration

* indicates fields that are mandatory

Email *

Password *

Confirm Password *

First name *

Surname *

Postcode *

Country *

Mobile phone number

Username *

Gender *

Year of birth *

When you sign up...

You will have access to all our online competitions, discounted offers and can post comments on our site.

You will also receive The Weekender newsletter sent every Thursday - it’s full of fantastic offers and ideas for the weekend. You can update your email preferences in your account page when you log in.

Other newsletters and emails

Homes & Property Newsletter - Yes I want to receive the weekly email with all the latest news on property in the capital

Occasionally we would also like to send you relevant emails detailing specific offers either from ourselves or carefully selected partners. If you would prefer not to receive these then please tick the appropriate boxes below. We will never pass on your details.

I do not want to receive additional offers and information from the Evening Standard

I do not want to receive additional offers and information sent by Evening Standard on behalf of carefully selected partners

Terms and Conditions

* I have read, understood and agree to be bound by the terms and conditions of Evening Standard

Registration

Mail Sent for Registration Confirmation.

A confirmation email has been sent. Please activate your account by clicking on the activation link sent in your mail box.

After more than a decade in development, GW said Sativex, an under-the-tongue cannabis spray which aims to ease MS patients' muscle stiffness, will become available on prescription in Britain and Spain in June.

The drugmaker — which grows Sativex's genetically cloned marijuana plants in secret locations around England — will receive £12.5 million from Germany's Bayer and Spain's Almirall, who are marketing the prescription drug, when it is formally approved.

Sativex became the world's first cannabis medicine to win regulatory approval in Canada in 2005. It is also being put through trials as a treatment for pain in patients with advanced cancer.

Dr Geoffrey Guy, chairman of the pharma group, said: "GW is transitioning from a late-stage development company to a commercial pharmaceutical business with excellent growth prospects."

The group posted a pre-tax loss of £2.7 million for the six months to March 31.